Terlipressin CAS:14636-12-5

Terlipressin is mainly used in patients with acute hepatic encephalopathy and cirrhosis for upper gastrointestinal bleeding due to bleeding from gastroesophageal varices. As a vasoconstrictor, Terlipressin causes smooth muscle contraction by stimulating V1 receptors on blood vessels, which reduces blood flow, especially in the venous system in the mesentery and gastrointestinal systems. This effect helps to reduce blood flow to gastroesophageal varices, thereby reducing the amount of bleeding and blood loss, while increasing coronary circulation and improving blood supply to the heart muscle. The efficacy of Terlipressin is widely used in the clinic and has been shown to effectively control acute bleeding conditions, reduce mortality and reduce the risk of recurrent bleeding. In addition, Terlipressin may also be used to treat other caused pathologic bleeding, such as gastrointestinal bleeding or uterine bleeding after gynecological surgery. However, the use of Terlipressin requires careful dose adjustment and monitoring of patient response to avoid adverse reactions such as hypertension or myocardial ischemia. During treatment, the doctor will evaluate the patient's condition and treatment response on a case-by-case basis to ensure safety and effectiveness.